tolic and systolic dysfunction, regular features of hyperpatients with hypertensive heart disease. In addition, the tensive heart disease. There are several treatment presence of hypertension in patients with AF constiapproaches that may be considered in such patients tutes an important risk factor for the development of ranging from interventions to prevent thromboembolic thromboembolic events and probably also selects out events, drugs and procedures for control of the venthose individuals who may be resistant to drug therapy. tricular response, and drug and non-pharmacologic AF in patients with hypertensive heart disease may lead therapy specifically designed to prevent AF or to restore to a number of serious clinical sequelae including normal sinus rhythm. This review article will cover each stroke, left atrial myopathy, left ventricular dysfunction, of these components of therapy of AF and will attempt and congestive heart failure. This needs to be treated to focus on those therapies that might be best suited aggressively since many patients may become quite for patients with hypertensive heart disease. symptomatic when AF develops in the setting of diasKeywords: atrial fibrillation; hypertension tiple wavelets participate. According to this hypothIntroduction esis, first postulated by Moe, these wavelets function Atrial fibrillation (AF) is the most common arrhythindependently of each other. 3 This principle was mia in clinical medicine. It accounts for a third of confirmed in experiments by Allessie and his coall of the arrhythmia Diagnostic Relate Group (DRG) investigators. 4 It would also appear that a minimum diagnoses 1 and afflicts millions of patients with and number of wavelets need to be present to perpetuate without overt heart disease. In the United States, the AF. There has been no evidence to date that AF that leading cause of AF is hypertension. The relationaccompanies hypertensive heart disease in any way ship between hypertension and AF is important for represents a different pathophysiologic entity. One several reasons. Patients who have AF in the setting would expect, however, that the presence of left of hypertension are frequently resistant to medical atrial dilatation and 'stretch' might make the atrium management. They are at higher risk for the developeven more prone to the development of multiple ment of thromboembolic events and have a very wavelets which would perpetuate this arrhythmia. high chance of developing a proarrhythmic event It is clear that patients with hypertensive heart disduring antiarrhythmic drug therapy. Hypertension ease do have abnormalities of atrial activation as evirepresents a risk factor for the development of AF denced by abnormal P waves on signal averaged or because it causes left atrial dilatation and can lead to surface ECG recordings. Left atrial dilatation also coronary artery disease and congestive heart failure, leads to alteration in electrophysiologic properties diseases associated with AF.
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2 Therefore, hypertenof the atrium such as shortening of refractoriness sion and AF are interdependent disease processes and prolongation of conduction time. 5 With changes and should be thought of, in many patients, as in left atrial dimension also come an increased risk comorbid conditions. for the development of atrial thrombus. 6 As discussed in this article, this represents one of the most Pathogenesis important aspects of the management of AF especially in patients with hypertension who are The predominant theory of pathogenesis is that AF particularly prone to the development of thromrepresents a re-entrant arrhythmia in which mulboembolic events. In addition to the electrophysiologic lesion in the atrium, it is likely that there are autonomic effects that might promote this arrhythmia. 7 Patients with hypertension are known to have sympathetic/ with the use of this particular agent is 'torsades de pointes' which is likely to occur in patients with parasympathetic imbalance which may make them even more prone to the development of this poor left ventricular function and those with relative bradycardia. Interestingly, torsades appears to occur arrrhythmia. There are no data that address this question specifically in patients with hypertensive most frequently following reversion to sinus rhythm especially in patients with sinus node dysfunction. heart disease.
The hypertrophied non-compliant left ventricle Another traditional agent used for this indication is intravenous procainamide. Again, published effipoorly accommodates increases in heart rate which is a regular feature of AF. In addition, over time, cacy is in the range of 50-80% in uncontrolled series. 11 The difficulty with assessing efficacy rates in uncontrolled heart rates can lead to left ventricular dilatation and further deterioration in left ventricuuncontrolled experiments is that there is a high placebo conversion rate in patients with AF of relalar systolic function. Thus, patients with a combination of AF and hypertension are particularly tively recent onset. The conventional dose of intravenous procainamide is in the range of 800-1200 mg prone to the development of congestive heart failure symptoms and signs. Whether or not simple control administered slowly over the course of 0.5-1 h. The principal liability of procainamide is systemic hypoof the heart rate in patients with hypertension would obviate these problems has not been decided. tension due to its vasodilator effects.
Most recently there has been a welter of inforIt is clear that a high priority in patients with hypertension should be to control the ventricular mation regarding the use of newer antiarrhythmic drugs for this indication. Flecainide and proresponse rate with appropriate drug or non-pharmacologic therapy.
pafenone appear to be effective both orally and intravenously for the acute termination of AF. For example, a single oral dose of 600 mg of pro-
Acute therapy of AF
pafenone appears to have an efficacy rate approaching 80-90% for the conversion of AF of relatively Patients with AF frequently require acute intervention for arrhythmia termination. Traditional recent onset (Ͻ3 to 7 days). 12 In general, the longer the period of observation, and the shorter the durmethods of heart rate control followed by a period of anticoagulation before rhythm reversion may not ation of antecedent AF, the higher the placebo conversion rate which should be subtracted from the be appropriate for some patients such as those with severe symptoms. Likewise, it may be in the active drug efficacy data. These drugs have the benefit of being very well tolerated even when used patient's benefit, or cost effective, to pursue indirect treatment methods of AF of relatively short durorally. Their principal liability is the development of atrial flutter with conduction to the ventricle in ation. Acute termination obviates the need for systemic anticoagulation and hospital admission. a 1:1 ratio in patients who have not had satisfactory AV nodal blockade.
13
This complication is Options for acute termination of AF include electrical and medical cardioversion. Although the efficacy infrequent and is not life threatening. The development of ventricular proarrhythmia, which is a major rate for electrical cardioversion is high (greater than 90% success in most series with transthoracic problem with the use of these drugs for ventricular indications, is virtually never seen during their use shocks), the procedure may be complicated. 8 There is the need for adequate anesthesia and a period of for atrial arrhythmias. Data regarding amiodarone are much less compelling. Although intravenous recovery of the procedure. There is a relatively high recurrence rate of the arrhythmia especially if antiamiodarone may be useful for the control of the ventricular response during AF in patients with haemoarrhythmic drug therapy has not been provided. Depending on the duration of the arrhythmia, there dynamic compromise, it does not appear to be any better than placebo in converting AF to sinus is a finite risk for the development of thromboembolic events either during the cardioversion or more rhythm in most clinical situations.
14,15
The drug that was developed specifically for this likely after, when atrial mechanical function may be lost. In a recent series published in abstract form, indication is intravenous ibutilide. 16 Although classified as a Class III antiarrhythmic drug, it is the incidence of complications from cardioversion was greater than 5% if one includes minor compliunusual in that it blocks the slow sodium channel rather than having any material effect on the delayed cations such as skin burns.
9
Because of the concerns with electrical cardioverrectifier potaassium currents. It does prolong the QT interval and prolongs atrial refractoriness like other sion, there has been an increasing interest in the use of medical therapy for the acute termination of AF. drugs in its same class. The drug is effective in converting AF to sinus rhythm in approximately 35-Most Class I and Class III drugs have been tested for this indication but there are only scant controlled 50% of patients. Its efficacy for atrial flutter is much better with 70% of patients with arrhythmia condata to support efficacy. For example, quinidine when administered in large oral doses has traditionverting to sinus rhythm within a few minutes of drug administration. The drug is very rapidly disally been used for termination of AF in patients with relatively well tolerated arrhythmias. The conventributed to other tissues which means that it has a very transient effect on the heart and the cardiac tional dose is in the range of 600 mg of a rapidly absorbed formulation such as quinidine sulfate, folconduction system. QT intervals, which may be massively prolonged during acute administration of lowed by a period of observation of approximately 2-4 h. Published efficacy rates for this mode of therthe drug, revert towards normal within 1-2 h of drug dosing. This accounts for the observation that the apy are in the range of 40-80%. 10 The principal risk drug will convert AF to sinus rhythm within several should be given to the use of oral rather than intravenous medication. Although the time to onset of minutes of drug administration during which time the patient is most susceptible to the development effect may be longer, there is less of a chance of haemodydnamic deterioration since the oral prepof torsades. In fact, torsades de pointes is the most important and frequent complication of ibutilide arations do not produce as much of a vasodilatory or negative inotropic effect as the parenteral forms. therapy. Sustained torsades was seen in approximately 1.7% of the cases in the clinical trials. NonPatients who have heart rate control with short acting oral or intravenous antiarrhythmic drug thersustained torsades occurred with a frequency of about 2.6% and rapidly responded to intravenous apy will frequently require chronic therapy with longer acting drugs. In order to improve patient magnesium and pacing therapy. Since torsades occurred while the patient was under close obsercompliance, sustained release preparations of verapamil or diltiazem, or long-acting beta-blockers such vation, no deaths or prolonged resuscitations were reported in the clinical trials. There appeared to be as nadolol may be preferred therapy in patients treated for this indication over the long term. Drug no untoward effect of ibutilide on the subsequent management of AF including drug therapy or electritherapy should be individualized predicated on such clinical parameters as the extent of left vencal reversion. There were no adverse events during an extended 3 month follow-up after ibutilide tricular dysfunction and the presence or absence of coronary artery disease. administration.
Despite the availability of methods to acutely terminate AF on initial presentation, many patients are Thromboembolism and use of not candidates for this approach. This may be anticoagulation because the arrhythmia is of uncertain duration so that there may be a concern about the presence of This topic has been covered in great detail in several good review articles. 18 It is clear from the literature atrial clot. In addition, patients who have AF of long duration are unlikely to respond to acute measures.
that AF is associated with a substantial risk of thromboembolic events. It is possible to risk stratify Finally, patients may already be on an antiarrhythmic drug which has potent electrophysiologic individuals for their proclivity to develop thromboembolic events based on a number of clinical varieffects. There are virtually no data regarding the addition of a second agent for arrhythmia reversion ables. Among these are congestive heart failure, left ventricular dysfunction, prior thromboembolic in such patients. In patients with hypertension, AF with a rapid ventricular response may produce events, left atrial dimension, and age. One of the most important of these risk variables is hypertendiverse haemodynamic alterations. For example, a rapid ventricular response in a patient with a poorly sion. Patients with hypertension may be three to five times more likely to develop a thromboembolic compliant left ventricle may cause systemic hypotension. In this clinical circumstance, judicious use event with AF than their normotensive peers. 19, 20 Therefore, patients who have AF in the setting of of drugs to slow the ventricular response may be warranted. This approach must be used quite cauhypertensive heart disease (left ventricular hypertrophy and left atrial dilatation) should always be contiously since many of these drugs themselves produce systemic hypotension which may confound sidered for anticoagulant therapy with coumadin. It is less clear that such individuals are protected with patient management. Most patients who have left ventricular hypertrophy are not candidates for drug the use of aspirin or any other antiplatelet drug such as ticlopidine. therapy with digitalis, the only intravenous drug available for this indication which does not produce While we know that patients with chronic AF and hypertensive heart disease are candidates for antivasodilatation and negative inotropy. Patients who have hypertensive heart disease with severe systolic coagulation, there is less certainty regarding the treatment of patients with hypertension without dysfunction (relatively end stage) are exceptions to this rule and may be treated with digitalis therapy overt structural heart disease and patients with paroxysmal AF of relatively short duration. These two acutely. 17 In contradistinction, many patients who have AF groups represent a particular clinical conundrum since they represent a large segment of the popuin the setting of hypertensive heart disease may present with hypertension. The explanation for this lation of patients with AF and because indiscriminate therapy of this patient group might place a large phenomenon is that these patients have intense sympathetic activation which leads to vasoconstricpercentage of them at risk without material benefit. We have learned from the transoesophageal echo tion and a hypertensive response. Here, the goal of therapy should be to slow the ventricular response literature that the time to the development of atrial thrombus is highly variable but certainly appears to and to lower blood pressure. Drugs which were ideally suited for this include the non-dihydropyridbe shorter than what was traditionally thought. 21 For example, patients with AF may develop atrial ine calcium blockers and beta-adrenergic blockers. There has even been some scant experience with 'smoke' or atrial clot within several hours of the onset of their arrhythmia. It would appear reasonantisympathetic drugs such as clonidine but this should be considered as accessory therapy to drugs able then to begin to consider thromboembolic prophylaxis for patients who have had AF for more such as verapamil, diltiazem, and short-acting betaadrenergic blockers such as esmolol, metoprolol, or than 1 or 2 days, especially in the presence of structural heart disease. What makes this decision even propranolol. In many of these clinical situations in which the patient is stable, strong consideration more treacherous is that many patients with AF are not aware of their arrhythmia and therefore assessof transoesophageal techniques as a part of the routine management of patients with atrial ment of the time of onset of the arrhythmia may be in gross error. fibrillation/flutter. For the time being, it would appear to be reasonable to use these techniques in Patients with minimal heart disease as mentioned previous represent another challenge in therapy.
patients in whom a period of systemic anticoagulation with coumadin is not feasible prior to converWhile it is clear that these patients must be protected from the development of thromboembolism sion, such as those with severe haemodynamic deterioration. The technique also lends itself to during attempts to convert the rhythm to sinus, it is not at all clear that they are at substantial risk of clinical situations in which patients who may have an absolute contraindication to systemic anticoagulthromboembolic events from the paroxysms alone. In none of the clinical trials to date have there been ation, such as prior bleeding diatheses. There is no a priori reason to believe that patients with hyperadequate numbers of these kinds of patients to reach firm conclusions. In addition, given the relatively tensive heart disease should represent any exception to the rule that transoesophageal echocardiography low thromboembolic rate in this population, an inordinately large number of patients would need is an accessory tool in the prevention of thromboembolic events in patients with AF, at least pending to be studied to reach any final conclusions. Many clinicans have resorted to the use of aspirin for this completion of definitive clinical trials. patient population on the principle that this represents less risky therapy. This may be even more
Chronic antiarrhythmic drug therapy
folly given the fact that these patients have not been studied in substantial numbers in clinical trials in Despite the advances in non-pharmacologic therapy for AF that will be mentioned later in this article, which aspirin has been employed.
Atrial flutter has traditionally been grouped with antiarrhythmic drugs remain the mainstay of therapy of most patients with atrial fibrillation and atrial AF in the consideration of acute and chronic therapy. This probably is inappropriate. Atrial flutter flutter. To date, there has been no information to prove that one or another form of heart disease causmay be a more organized arrhythmia in which atrial mechanical function is better preserved. In addition, ing AF is intrinsically more amenable to therapy with one or another antiarrhythmic drug. Consedrug therapy for acute termination of atrial flutter has traditionally been more effective compared with quently, drug therapy for AF remains an empiric science. Patients with hypertensive heart disease attempts to convert AF. Pacing therapy may also be used to entrain and terminate atrial flutter and this and AF may be candidates for any of the Class I or Class III antiarrhythmic drugs currently available. has been carried out in patients after cardiac surgery as well as on medical services. The assumption that What may make one or another agent more or less attractive in hypertensive patients may be their relaatrial flutter does not require systemic anticoagulation, however, is probably not warranted. 22 Atrial tive propensity to arrhythmia aggravation. In addition, most of the older drugs and some of the flutter is infrequently 'pure', and may be punctuated by periods of AF. In addition, many patients with newer agents have the potential for organ toxicity which may be a particular problem in patients with atrial flutter do not have good atrial mechanical function and this cannot be ascertained from surface hypertension who are usually being treated with other pharmacologic agents. Given the liability of ECG recordings. For the present, it is reasonable to consider anticoagulation therapy for all patients drugs used for the preservation of sinus rhythm, it is incumbent upon the treating physician to be as with atrial flutter especially those who are to undergo conversion to sinus rhythm and in patients certain as possible that the drugs that they will select for therapy will benefit the patient with the least with structural heart disease.
The technique of transoesophageal echocardiograchance of producing harm. The relative benefits and risks of antiarrhythmic phy, particularly using omni-plane transducers, has revolutionized the approach to patients with AF and drugs used for this indication are displayed in Table 1 . Because of their potential to cause proatrial flutter. Several important clinical principles have either been confirmed or refuted using this arrhythmia, many of these drugs need to be started in the hospital under close observation. It should be technique. For example, the time of the development of clot has come to be challenged as well as remembered that although we have traditionally focused on ventricular proarrhythmia as the princithe period of time required using systemic anticoagulation with coumadin for the resolution of atrial pal liability of antiarrhythmic drugs used for ventricular indications, in the realm of treating patients clot. Whereas 2-3 weeks of systemic anticoagulation was considered adequate for this purpose, the transwith atrial arrhythmias bradyarrhythmias and atrial tachyarrhythmias may be more important. This peroesophageal literature has suggested that this may be an inadequate period of anticoagulation and that tains particularly to patients who have intrinsic conduction system disease or who have conduction patients may require 4-6 weeks of anticoagulation before an atrial clot is either dissolved or sufficiently block caused by concomitant drugs. Although there has been substantial experience endothelialized such that it cannot move from the atrial cavity. 23 Despite these interesting observations with a number of drugs for this indication, few have been studied as well as the Class IC antiarrhythmic and their impact on clinical management, few of these principles have been conclusively proven in drugs, flecainide and propafenone. In fact, both of these agents have been presented to the Food and large clinical trials. Several such studies are in progress to answer key questions regarding the use Drug Administration's Cardiorenal Advisory Com- 27 The relative benefit of such mittee. Flecainide has obtained an indication for treatment of AF and propafenone probably will aggressive drug therapy in relation to non-pharmacologic options has not been sufficiently addressed within the next several months. As mentioned previously, these drugs have the potential to work rapin the literature to make any value judgment. Finally, patients who have relatively infrequent epiidly to terminate atrial arrhythmias. This property is distinct from their ability to prevent recurrence sodes of AF may be considered for periodic therapy.
Here the concept is to use the drug for a short period and it should not be assumed that they will necessarily be effective for both indications in the same of time to terminate and/or prevent recurrence of the arrhythmia. Drugs with a relatively short time to patient.
These drugs have particular promise for the treateffect are particularly useful in this regard and may be combined with AV nodal drugs as well as sedament of patients with AF and hypertensive heart disease. 24 There has now been substantial data gathtives which lessen sympathetic activation and thus facilitate more prompt rhythm reversion. ered to prove that hypertension causes a severe repolarization lesion in the ventricle. Not only may Antiarrhythmic drugs which are used for the prevention of recurrent AF may be initiated following hypertension cause a prolongation of repolarization but, perhaps more importantly, it leads to marked restoration of sinus rhythm or prior to attempted electrical cardioversion. The benefit of the latter heterogeneity in repolarization manifest either as dispersion of refractoriness or by dispersion in the approach is that there may be a higher likelihood of maintaining sinus rhythm once the rhythm has QT interval which has become a popular non-invasive method to measure disparity in recovery of excitreverted. There have been no organized studies to prove the relative benefit of these approaches and so ability. 25 Given these abnormalities, it is reasonable to avoid the use of drugs which have an effect on the decision is usually based on other concerns, many of which are logistical. repolarization which may not be quantifiable or predictable. Class 1C drugs have the benefit of not causing changes in ventricular repolarization and thus
Special considerations
should not aggravate the electrophysiologic lesion that is a regular part of left ventricular hypertrophy. AF Wolff Parkinson White Syndrome As mentioned previously, however, these drugs may slow atrial conduction and thus propagate atrial Patients with hypertrophic cardiomyopathy (not related to hypertensive heart disease) may be partiflutter which may be conducted rapidly over an unprotected AV node. They may also have an effect cularly disposed to the development of AF in the setting of pre-excitation syndromes such as Wolff on sinus, AV nodal function or His Purkinje tissue especially in patients with antecedent conduction Parkinson White Syndrome. These patients must be approached and treated quite carefully since drugs abnormalities (such as the elderly). 26 As mentioned earlier, there are no specific data which block AV nodal conduction may also cause systemic hypotension and abrupt haemodynamic relating to the relative safety and efficacy of other newer agents such as sotalol and amiodarone for the deterioration. The treatment of AF in this clinical scenario requires the use of drugs which have a prevention of AF in patients with hypertensive heart disease. Like the Class IA drugs, sotalol does proretardant effect on accessory pathway tissue, such as Class IA or Class IC antiarrhythmic drugs. Traduce a repolarization effect which may complicate the treatment of patients with hypertension, ditional drug therapy has been intravenous procainamide which has the liability of systemic hypotenalthough this has not been adequately studied. Amiodarone may be used quite effectively for sion. 28 Class IC drugs may be used in this clinical situation. They are not available intravenously in patients with hypertensive heart disease, especially the United States (although they are in several other this indication. For patients who are severely countries). For patients who are not haemodynamicompromised haemodynamically, prompt electrical cally compromised, oral dosing with a 1C agent in cardioversion is mandatory. doses sufficient to produce AF termination (up to 600 mg as a single dose) may be highly effective for AF after coronary artery bypass graft surgery internal electrical cardioversion is appealing. There are abundant animal data to suggest that this can be This represents a very common clinical scenario.
accomplished with a relatively low amount of delivPatients after coronary surgery and other forms of ered energy. 32 Unfortunately, in order to reduce the cardiac surgery are particularly prone to the develnumber of joules delivered to a level below which opment of AF. The incidence of this arrhythmia in pain may be felt, it is necessary to use multiple lead these populations has been reported to be as high as systems including perhaps a coronary sinus lead 40%. 29 Prophylactic measures such as beta adrewith their attendant complications. Perhaps the two nergic blockade have been only partially effective. most important questions having to do with atrial In a recent series, prophylaxis with acebutolol defibrillation are the sensation of the shock, and prereduced the incidence of AF from 40% in untreated cipitation of ventricular fibrillation. Given the fact patients to approximately 20%. 30 Thus, despite our that patients may undergo repeated shock terminbest efforts, patients after cardiac surgery frequently ations of AF, causation of any discomfort may be have AF which represents both a medical and econproblematic. Finally, shocks delivered intracardiac omic problem. These patients are frequently symphave the potential to produce ventricular fibriltomatic and AF may impede their surgical recovery.
lation. Even a relatively low occurrence rate would In addition, post coronary artery bypass graft be unacceptable for patients who receive a stand (CABG) AF is responsible for an increased length of alone atrial defibrillator device and so this must be stay of anywhere from 2-3 days which results in a completely prevented. substantial increase in this cost of the very common Although other forms of supraventricular arrhythsurgical procedure.
mia have been amenable to catheter ablation tech-A variety of antiarrhythmic drugs have been used niques, AF has not. There has been some prelimito attempt to treat AF once it has occurred in the nary work accomplished to date which has post CABG setting. There are no data to prove that attempted to define the feasibility of creating mulone drug is necessarily superior to any others. For tiple endocardial lesions for the interruption of repatients with preserved left ventricular function, the entrant circuits in the atrium, but this is not yet feas-1C drugs have been used with benefit and appear to ible clinically and is unlikely to be for some time. A be well tolerated. Sotalol and amiodarone have also principal problem with ablation of AF is the diffuse been used with benefit although the latter drug sufnature of the disease and the need for multiple fers the liability of a fairly long duration of time to lesions. This predisposes patients to thromboemcomplete loading. This is of particular importance bolic events which has been one of the major limitsince AF post CABG is a transient arrhythmia, rarely ing factors in the early clinical experience. Conlasting more than 4-6 weeks following surgery. In a versely, atrial flutter is quite amenable to an ablation series of patients followed within that time frame, approach. 33 There have now been several reports in nearly all patients had reverted to sinus rhythm no the literature of successful atrial flutter ablation with matter what form of therapy had been prescribed recurrence rates of less than 20-30% in the year folduring their post CABG hospitalization. 29 It should lowing the initial procedure. Since atrial flutter, be remembered that these patients are at risk for the especially the typical form, probably represents a development of thromboembolic events and theremacro re-entrant circuit, it is possible to establish fore must be treated with systemic anticoagulation lesions in the right atrial cavity at the isthmus which as do all other patients with this rhythm disorder.
would be expected to preclude re-entrant arrhythmias in that region. Unfortunately, recurrence will always remain an issue since many patients with Non-pharmacologic therapy of AF atrial flutter are also predisposed to the development of AF. In fact, in the literature, this is the As mentioned earlier, pacing may be used to entrain and interrupt atrial flutter. This technique is arrhythmia most often seen in patients with symptom recurrence. especially useful for so-called 'typical' atrial flutter in which it is believed that one large re-entrant cirWithin the realm of catheter ablation techniques is AV nodal ablation or modification. 34 AV nodal cuit participates in activation of the atrium. It is an especially useful technique in patients after coronablation with radiofrequency energy is a relatively simple technique which can be carried out in a very ary artery bypass graft surgery who already have atrial wires in place. Pacing for the prevention of short period of time with nearly 100% success rates. For those patients who cannot have AV nodal AF is much more controversial. 31 Although there are some data to suggest that patients who undergo atrablation from the right side of their heart, left-sided approach can be used with a nearly 100% success ial-based pacing have a better chance of maintaining sinus rhythm, this information is not definitive. One rate. Interruption of AV nodal conduction does not prevent the atrial arrhythmia and therefore patients would expect that pacing might be especially useful for prevention of AF in patients with intrinsic sinus still require anticoagulation. These patients all require a ventricular pacemaker to support heart node disease since bradycardia may predispose to the development of multiple re-entrant circuits in rate. For patients who have paroxysmal AF, a pacemaker with a programmable automatic mode switch the atrium. There are currently at least two clinical trials in progress which are examining this issue in feature may be useful to allow sinus rhythm with normal AV conduction whenver possible. For a prospective fashion.
Shock termination of AF is very effective and patients with chronic AF the approach is simpler with only ventricular based pacing employed. AV therefore the concept of providing automatic nodal modification, or attempting to ablate only the sive patient management including rate control measures, anticoagulation, and judicious use of drugs slow pathway to attenuate the heart rate response, has several advantages but there is insufficient and non-pharmacologic therapy remain the standard for the treatment of patients with AF in the experience with this procedure to warrant its widespread acceptance. In the small studies that have context of hypertensive heart disease. been published to date, there has been an inordinately large number of patients who have gone on Acknowledgement to complete heart block. This may happen unexpectedly with dire consequences. Currently, we do not
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Symposium. Finally, the most successful non-pharmacologic approach to AF has undoubtedly been an operative procedure. Over time, several have attempted vari- is founded on the concept that there are multiple re- some cases another tachycardia such as atrial flutter.
